Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
PRAME family member 25 (PRAMEF25)
- Target
- PRAMEF25
- Molecular classification
- Leucine-rich repeat protein (LRR protein), Ubiquitin-like ligase-substrate adaptor (predicted, based on gene function annotation), Cancer/testis antigen family (by homology with PRAME family), Other
01
Overview
PRAME family member 25 (PRAMEF25) is a human protein-coding gene that belongs to the PRAME (Preferentially Expressed Antigen in Melanoma) family of cancer/testis antigen genes and is characterized by a leucine-rich repeat (LRR) protein domain organization. While the PRAME family is well-studied for its role as a cancer biomarker and potential immunotherapeutic target, and is involved in germline development and pluripotency, the specific biological function of PRAMEF25 remains largely uncharacterized. Computational predictions suggest it may function as a ubiquitin-like ligase-substrate adaptor and participate in cytoplasmic protein degradation via the Cul2-RING ubiquitin ligase complex. There are no current reports establishing PRAMEF25 as a drug target, and no approved therapeutic agents, biomarkers, or known safety issues are associated with this specific family member. Most available data and clinical implications pertain to other PRAME family proteins, with PRAMEF25's precise functional and clinical importance remaining unknown.
- Other names
- PRAMEF25PRAME family member 25PRAME family member 25, putativePRA25_HUMAN (UniProt short name)Gene symbol: ENSG00000229571 (Ensembl)
02
Biological functions
Predicted: Ubiquitin-dependent protein catabolic process (involvement in protein degradation as part of the Cul2-RING ubiquitin ligase complex)Predicted: Adapter activity (ubiquitin-proteasome system)By family analogy: Roles in germline development, pluripotency, and transcriptional regulation (based on PRAME family members)
03
Disease associations
No direct, curated role for PRAMEF25 itself; limited disease associationPRAME family in general: Cancer (biomarker and potential immunotherapy target), reproductive disordersPRAMEF25 in GeneCards: Hypertropia, paralytic squint (weak gene-disease link)Other
Beyond the preview
Go deeper on PRAME family member 25 (PRAMEF25).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on PRAME family member 25 (PRAMEF25).